ARGX - Halozyme expands license agreement with argenx for Enhanze Technology

Halozyme Therapeutics (HALO) and argenx (ARGX) are expanding their existing global collaboration and license agreement that was signed in February 2019. Under the expanded deal, argenx gained the ability to exclusively access Halozyme's ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration.To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.Previously: Halozyme out-licenses Enhanze to argenx for $30M upfront (Feb. 4, 2019)

For further details see:

Halozyme expands license agreement with argenx for Enhanze Technology